gip/glp-1 agonists Dual receptor agonists: New advances for treating type-2 diabetes Holding GLP-1 Agonists Prior to

2020;12:e7472

PrymaLab focuses on US-made research peptides, transparent COAs, and educational content built around the science not the hype

In the U.S., about 6% of adults currently use GLP-1s, and 12% have used them in the past (2024 data) (Mozafariun 2025)

Only through interdisciplinary collaboration, open science, and technology-driven democratization of care can the field transition from symptomatic palliation to genuine disease modification (Table 4)

Conclusions A comprehensive strategy for obesity management using GLP-1 and GIP agonists must consider both metabolic and psychological factors

Boost Immunity: Glutathione is essential for the proper functioning of the immune system